Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.230 -0.240 (-9.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Iovance (IOVA) Q3 2025 Earnings Call Transcript ↗
Iovance (IOVA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? ↗
Iovance has a long way to go to get to a break-even point, but the company has been showing progress. 
Via The Motley Fool
News headline image
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street ↗
Wall Street may be overestimating these companies' potential. 
Via The Motley Fool
News headline image
Top movers in Thursday's session ↗
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Why Are IOVA Shares Rising Today? ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’ ↗
Via Stocktwits
News headline image
Top stock movements in today's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Gapping stocks in Thursday's session ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Examining the Future: Iovance Biotherapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
Via MarketMinute
Topics Initial Public Offering Regulatory Compliance Workforce
News headline image
Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of... 
Via MarketMinute
Topics Intellectual Property Workforce
News headline image
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health ↗
Is there a glimmer of hope for either of these underperforming healthcare companies? 
Via The Motley Fool
News headline image
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? ↗
Investors have certainly seen explosive gains from shares of biopharma companies in similar situations. 
Via The Motley Fool
News headline image
Can This Beaten-Down Stock Bounce Back? ↗
This biotech company is innovative, but the market demands more than that. 
Via The Motley Fool
News headline image
If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today ↗
The company hasn't been popular among investors since winning its first FDA approval more than a year ago. 
Via The Motley Fool
News headline image
Why Iovance Biotherapeutics Stock Got Mashed on Monday ↗
The company announced a flotation of its common shares that is potentially quite dilutive. 
Via The Motley Fool
News headline image
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗
 
Via Benzinga
News headline image
1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street ↗
Time is running out for the company to mount a comeback. 
Via The Motley Fool
News headline image
Why Iovance Biotherapeutics Stock Was Climbing Today ↗
One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country. 
Via The Motley Fool
News headline image
Intel, Plymouth Industrial REIT, Premier And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 ↗
All three of these companies are entering a period of what could produce unparalleled top- and bottom-line growth. 
Via The Motley Fool
News headline image
Why Iovance Biotherapeutics Stock Plummeted Today ↗
The company's top line nearly doubled. 
Via The Motley Fool
News headline image
What 7 Analyst Ratings Have To Say About Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
Pinterest Posts Downbeat Q2 Earnings, Joins Twilio, Trade Desk And Other Big Stocks Moving Lower In Friday Pre-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving before the opening bell on Friday? ↗
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.